Print Page   |   Sign In   |   Join ISSX
ISSX News: General

Towards a Consensus on Applying Quantitative LC‐MS/MS Proteomics in Translational Pharmacology

Tuesday, July 2, 2019   (0 Comments)
Posted by: ISSX
Share |

 

Clinical Pharmacology & Therapeutics 

Towards a Consensus on Applying Quantitative LC‐MS/MS Proteomics in Translational Pharmacology Research: A White Paper

Bhagwat Prasad, Brahim Achour, Per Artursson, Cornelis ECA Hop, Yurong Lai, Philip C Smith, Jill Barber, Jacek R Wisniewski, Daniel Spellman, Yasuo Uchida, Michael Zientek, Jashvant D. Unadkat, Amin Rostami‐Hodjegan

https://doi.org/10.1002/cpt.1537

Abstract:

Quantitative translation of information on drug absorption, disposition, receptor engagement and drug‐drug interactions from bench to bedside requires models informed by physiological parameters that link in vitro studies to in vivo outcomes. To predict in vivo outcomes, biochemical data from experimental systems are routinely scaled using protein quantity in these systems and relevant tissues. Although several laboratories have generated useful quantitative proteomic data using state‐of‐the‐art mass spectrometry, no harmonized guidelines exit for sample analysis and data integration to in vivo translation practices. To address this gap, a workshop was held on September 27th and 28th, 2018, in Cambridge, MA, with 100 experts attending from academia, the pharmaceutical industry and regulators. Various aspects of quantitative proteomics and its applications in translational pharmacology were debated. A summary of discussions and best practices identified by this expert panel are presented in this ‘White Paper’ alongside unresolved issues which were outlined for future debates.

American Society for Clinical Pharmacology & Therapeutics (ASCPT) This article is protected by copyright. All rights reserved.


Association Management Software Powered by YourMembership  ::  Legal